Since conflicting/opposite impacts of SIRT3 on tumor growth have been reported in the literature (11, 15, 29, 30), we thus performed patient survival analysis as well as in vitro and in vivo experiments to evaluate the role of SIRT3 on pancreatic cancer development in the context of KRAS activation. Here, KRAS is linked to familial pancreatic carcinoma.